Sanofi ends Clostridium difficile vaccine trials.
Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the phase 3 Cdiffense clinical trial program concluded that the probability that the study will meet its primary objective is low. Based on this, Sanofi has decided to discontinue clinical development of its experimental C. difficile vaccine, to focus on six key vaccine projects currently in development.